Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Total Current Liabilities (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Total Current Liabilities data on record, last reported at $22.7 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 20.13% year-over-year to $22.7 million; the TTM value through Dec 2025 reached $22.7 million, down 20.13%, while the annual FY2025 figure was $22.7 million, 20.13% down from the prior year.
  • Total Current Liabilities reached $22.7 million in Q4 2025 per AMLX's latest filing, down from $25.8 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $91.6 million in Q1 2024 and bottomed at $17.4 million in Q4 2021.
  • Average Total Current Liabilities over 5 years is $42.8 million, with a median of $32.6 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: soared 167.93% in 2022, then crashed 80.43% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $17.4 million in 2021, then skyrocketed by 167.93% to $46.6 million in 2022, then surged by 76.02% to $82.0 million in 2023, then crashed by 65.38% to $28.4 million in 2024, then decreased by 20.13% to $22.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $22.7 million in Q4 2025, $25.8 million in Q3 2025, and $21.4 million in Q2 2025.